Updated:
Owlet
Owlet launched in 2012, spun out of Brigham Young University's engineering labs after co-founder Kurt Workman's wife woke repeatedly in a panic, checking...
Owlet
Owlet launched in 2012, spun out of Brigham Young University's engineering labs after co-founder Kurt Workman's wife woke repeatedly in a panic, checking if their newborn son was still breathing. The initial product, a smart sock that tracked an infant's heart rate and oxygen levels, raised over $1.8 million on Kickstarter in 2015 and hit $7 million in revenue that first sales year. The company went public via a SPAC merger in 2021 and, after a bruising regulatory process, received FDA De Novo clearance for its BabySat monitor in late 2023 — transitioning from a wellness gadget to a regulated medical device. Owlet operates a direct-to-consumer hardware model with a recurring software layer. The core product is the FDA-cleared Dream Sock, which monitors an infant's pulse rate and oxygen saturation and streams data to a parent's smartphone. The companion Owlet Dream App requires a subscription for historical data trends, real-time alerts, and pediatric sleep analysis. Revenue splits between device sales and software subscriptions, with the company reporting roughly 350,000 active app users as of early 2024. In November 2023, Owlet announced a strategic partnership with Wheel, a telehealth platform, to connect parents monitoring their infants with on-demand pediatric consultants — a first step toward a care-delivery ecosystem. The company sells primarily in North America and the United Kingdom, with limited retail presence in Target, Best Buy, and Amazon. As a public company (NYSE: OWLT), Owlet is run by CEO Jonathan Harris, who took the helm in mid-2023 as the firm navigated its post-clearance commercial ramp. Headcount has fluctuated with restructuring; the company employed roughly 120 people as of its 2024 filings, down from a peak near 200. There are no known adjacent investment vehicles or family-office structures — Owlet is a pure-play consumer health tech company, not a family office or asset manager. In May 2024, the firm launched its FDA-cleared BabySat in the U.S. market, filling the medical-grade monitor gap it had promised for a decade. The structural distinction for Owlet lies in its regulatory moat. No other direct-to-consumer infant monitor holds FDA De Novo clearance for over-the-counter pulse oximetry in the home. That clearance — requiring clinical trials, software validation, and a quality management system — creates a barrier that competitors like Nanit or Miku have not crossed. The company's bet is that the regulatory seal, combined with a recurring software subscription, produces a margin profile and customer retention curve that pure-hardware or app-only rivals cannot replicate.
General information
Firm type
Asset Manager
Year founded
2012
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Lehi
Corporate office
Lehi, UT, United States
Principals
Kurt Workman
Co-Founder and President
Jonathan Harris
Chief Executive Officer
Sector focus
Frequently asked questions
Is Owlet's infant monitor a regulated medical device or a wellness product?
As of late 2023, the Dream Sock is an FDA De Novo-cleared medical device, specifically for monitoring heart rate and oxygen saturation in infants. The company's earlier Smart Sock was marketed as a wellness product and faced FDA warning letters in 2021. The clearance marks a fundamental regulatory shift — Owlet can now make clinical claims that competitors cannot. The medical-grade version is sold as BabySat, while the consumer Dream Sock shares the same hardware with restrictions on medical-grade alerts.
How does Owlet generate revenue beyond the hardware device?
Owlet's business model combines one-time device sales with recurring subscription revenue. The Owlet Dream App charges parents a monthly or annual fee for access to historical sleep data, health trend analytics, and real-time alert customization. The company has cited subscription attach rates as a key metric but does not break out subscription-specific revenue in public filings. A partnership with Wheel, announced in November 2023, suggests ambition to layer telehealth services atop the monitoring data.
Who runs day-to-day operations at Owlet?
Jonathan Harris is the Chief Executive Officer, appointed in mid-2023. Kurt Workman, who co-founded the company and served as CEO for its first decade, remains as President and a board member. Harris has a background in consumer health technology and joined during the company's pivot from a venture-backed wellness startup to a regulated medical device firm. Public filings list Harris as the principal executive officer.
Does Owlet operate any venture investment or family office structure?
No. Owlet is a publicly traded operating company (NYSE: OWLT), not a family office, investment firm, or asset manager. There is no evidence of a separate family office, foundation, or investment vehicle tied to the Workman family or other founders. The firm's capital comes from public equity and debt markets, not a single-family balance sheet.
What is Owlet's regulatory status in markets outside the United States?
Owlet sells its consumer monitoring products in the United Kingdom and has received CE marking for distribution in the European Union, though specific product availability varies. The FDA clearance is U.S.-specific and does not apply to international markets. The company has not disclosed whether it will seek equivalent medical device authorizations from the UK's MHRA or the EU's notified bodies for the BabySat configuration.
What happened with Owlet's SPAC merger and subsequent market performance?
Owlet merged with Sandbridge Acquisition Corporation in July 2021, listing on the NYSE at a valuation near $1.1 billion. The stock traded well below that level through 2022 and 2023 as the FDA warning letter and product transition depressed revenue. The firm underwent multiple restructurings and a reverse stock split to maintain the exchange listing. As of mid-2024, the market capitalization remained materially below the de-SPAC valuation.
Are there competing infant monitors with similar FDA clearance?
As of mid-2024, no direct-to-consumer infant pulse oximeter holds similar FDA De Novo clearance. Hospital-grade monitors from Medtronic, Masimo, and GE Healthcare are regulated but sold into clinical settings. Consumer competitors such as Nanit, Miku, and Cubo AI offer video and motion-sensing monitors but make no medical claims. Owlet's regulatory moat is narrow but genuine — the company holds the only over-the-counter clearance in the category.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: